MARKET

PMN

PMN

Promis Neuroscie
NASDAQ
3.760
-0.220
-5.53%
After Hours: 3.690 -0.07 -1.86% 19:30 11/11 EST
OPEN
4.090
PREV CLOSE
3.980
HIGH
4.219
LOW
3.690
VOLUME
111.86K
TURNOVER
--
52 WEEK HIGH
27.40
52 WEEK LOW
2.780
MARKET CAP
33.72M
P/E (TTM)
-0.2981
1D
5D
1M
3M
1Y
5Y
1D
ProMIS Neurosciences: Buy Rating and Unchanged $18 Price Target on PMN310’s Selective Amyloid Targeting
TipRanks · 2d ago
Weekly Report: what happened at PMN last week (1102-1106)?
Weekly Report · 2d ago
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
NASDAQ · 11/04 13:38
ProMIS Neurosciences Is Maintained at Buy by Roth Capital
Dow Jones · 11/02 18:13
ProMIS Neurosciences Price Target Cut to $15.00/Share From $29.00 by Roth Capital
Dow Jones · 11/02 18:13
Roth Capital Maintains Buy on ProMIS Neurosciences, Lowers Price Target to $15
Benzinga · 11/02 18:03
Roth MKM Releases a Buy Rating on ProMIS Neurosciences (PMN)
TipRanks · 11/02 16:36
Analysts Offer Insights on Healthcare Companies: ProMIS Neurosciences (PMN), OmniAb (OABI) and Repligen (RGEN)
TipRanks · 11/02 16:16
More
About PMN
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

Webull offers Promis Neurosciences Inc stock information, including NASDAQ: PMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PMN stock methods without spending real money on the virtual paper trading platform.